CLINICAL CARDIAC
BP CONTROL WITH CURRENT THERAPY
It has been shown that of those treated for hypertension, only 13 % had their blood pressure( BP) controlled.
Prof James Ker
There are many possible reasons for this but an emerging factor is the non-use of proven treatment strategies.
Monotherapy at increasing doses: Starting with monotherapy and then increasing the dose can be effective in reducing the blood pressure. However, as the dose increases, the side effects will increase.
This happens with diuretics, betablockers and calcium-channel blockers but not RAAS-blockers. There could be an exception when treating the very elderly, as more than one drug may increase hypotension and have serious side effects. One can start with a low dose and later increase the dose to first check that hypotension is not present. Sequential monotherapy: Trying to
The Boehringer Ingelheim
TRILOGY in Hypertension *
find the right monotherapy by switching from one to the other after a time on one is a very time-consuming strategy, which can make the patient lose confidence in the doctor and increase non-adherence.
Initial monotherapy and later combination therapy: Some guidelines support the strategy of initiating one drug with an effective
dose and then if control is not achieved, adding a second or even a third drug. This method is based on the rationale that due to different pathogenetic mechanisms, the drug combinations have a much greater BP-lowering capacity than monotherapy. This strategy makes it possible to increase the control rate from about one third in monotherapy to now two-thirds of hypertensive patients having controlled BP. It is thought that with different drugs, the different pathogenetic mechanisms are inhibited in a complimentary way. It is also possible to achieve control with lower doses of both or all of the drugs employed in the combination, which reduces the risk of side effects and increases the adherence rate.
Currently, the preferred combinations employ a RAAS-blocker( ACE-Inhibitor or ARB) with a diuretic such as indapamide, preferably, or a thiazide, or RAAS-blocker with a calcium channel blocker or a calcium channel blocker with a diuretic.
TELMISARTAN 40 / 80 mg
TELMISARTAN + HCTZ
TELMISARTAN + AMLODIPINE
FIRST AND ONLY ARB § INDICATED FOR THE REDUCTION OF MORTALITY & MORBIDITY 1 †
THE MOST COMMON SPECIALIST CHOICE
WHEN CHOOSING AN ARB § / HCTZ #
COMBINATION 2 ‡
COMPLIANCE RATES OF
≥ 98,4 %,
ONLY 19 % OF PATIENTS REQUIRING ADD-ON THERAPY 3
* Treatment in essential hypertension † For high cardiovascular risk patients ‡ Most commonly prescribed ARB / HCTZ single pill combination
§
ARB = Angiotensin Receptor Blockerer # HCTZ = Hydrochlorothiazide
References: 1. MIMS July 2016. 7.3.9 Angiotensin receptor antagonist; 140-151. 2. Qlikview scripting data representing 85 % of the funded market. 3. Neldam S, Edwards C, Lang M, et al. Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40 – 80 mg Plus Amlodipine 5 or 10 mg in Patients.
S3 PRITOR ® 40 mg. Each tablet contains telmisartan 40 mg. Reg. No. 33 / 7.1.3 / 0022. S3 PRITOR ® 80 mg. Each tablet contains telmisartan 80 mg. Reg. No. 33 / 7.1.3 / 0023. S3 CO-PRITOR ® 40 / 12,5 mg. Each tablet contains telmisartan 40 mg and hydrochlorothiazide 12,5 mg. Reg. No. 35 / 7.1.3 / 0347. S3 CO-PRITOR ® 80 / 12,5 mg. Each tablet contains telmisartan 80 mg and hydrochlorothiazide 12,5 mg. Reg. No. 35 / 7.1.3 / 0348 S3 TWYNSTA ® 40 / 5 mg tablets. Each tablet contains 40 mg telmisartan and 5 mg amlodipine base( as besylate salt). Reg. No. 44 / 7.1.3 / 0857. S3 TWYNSTA ® 40 / 10 mg tablets. Each tablet contains 40 mg telmisartan and 10 mg amlodipine base( as besylate salt). Reg. No. 44 / 7.1.3 / 0858. S3 TWYNSTA ® 80 / 5 mg tablets. Each tablet contains 80 mg telmisartan and 5 mg amlodipine base( as besylate salt). Reg. No. 44 / 7.1.3 / 0859. S3 TWYNSTA ® 80 / 10 mg tablets. Each tablet contains 80 mg telmisartan and 10 mg amlodipine base( as besylate salt). Reg. No. 44 / 7.1.3 / 08.
For full prescribing information refer to the package insert approved by the medicines regulatory authority. Applicant details: Ingelheim Pharmaceuticals( Pty) Ltd, 407 Pine Ave, Randburg, South Africa. Tel: + 27( 011) 348-2400. Cpy. Reg. No. 1966 / 008618 / 07. BI Ref No. GPM-TWPRICPR-0001-ZA.
Combination therapy first: Two-drug combination as an initial first step could be the preferred strategy. Some guidelines advocate this strategy when the initial blood pressure is ≥160 / 100mmHg. However, the authors state that they believe this strategy should be used more widely as the preferred initial step. Improvements in adherence rates have been demonstrated with single-pill combinations, which has variable doses and improve adherence rates.
Combination therapy is associated with more timely, faster and greater protective effects. In randomised trials, it was shown that the initial combination of a RAAS-blocker with a calcium channel blocker compared to monotherapy with the corresponding components, BP reductions were still visible after six weeks in the combination group. It took longer for the monotherapy components to catch up.
Initial combination treatment strategy may improve long-term BP control in a shorter time.
In two large cohorts, it was shown that initial combination treatment strategy discontinuation was significantly less. In two observational studies, starting with a combination strategy, there was much better cardiovascular protection with combinations from 26 %-34 %.
Many randomised blinded clinical trials in which BP was reduced to 140 / 90mmHg or less, the vast majority of patients needed a combination of drugs.
References available on request.
46 MAY 2017 | MEDICAL CHRONICLE